Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adoptive T-cell therapy

H M Lokhorst1, D Liebowitz

  • 1Department of Hematology, University Hospital, Utrecht, The Netherlands.

Seminars in Hematology
|February 16, 1999
PubMed
Summary
This summary is machine-generated.

Adoptive immunotherapy shows promise for multiple myeloma treatment. Donor leukocyte infusions (DLIs) achieved a 62% response rate in relapsed patients, while autologous T cells aided lymphoma recovery post-transplant.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Leukemia·2017
Same author

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Leukemia·2017
Same author

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma.

Bone marrow transplantation·2017
Same author

A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.

Therapeutic advances in hematology·2016
Same author

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma.

Clinical pharmacology and therapeutics·2016
Same author

Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients.

Bone marrow transplantation·2016
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Area of Science:

  • Immunology
  • Oncology
  • Cellular Therapy

Background:

  • Adoptive immunotherapy, transferring immune cells, is a promising cancer treatment.
  • Its potential for multiple myeloma and lymphoma is under investigation.

Purpose of the Study:

  • To explore adoptive immunotherapy using donor leukocyte infusions (DLIs) and autologous T cells for multiple myeloma and lymphoma.

Main Methods:

  • DLIs were administered to 17 multiple myeloma patients post-bone marrow transplant (BMT).
  • Autologous T cells, expanded via anti-CD3/CD28, were infused into 8 lymphoma patients post-BMT.

Main Results:

  • DLIs in multiple myeloma: 62% response rate (37% complete response) in 16 evaluable patients. Graft-versus-host disease occurred in 9 patients.

Related Experiment Videos

  • Autologous T cells in lymphoma: Granulocyte recovery observed around day 14 in 6 evaluable patients. Two patients experienced severe autoimmune toxicity.

    • Conclusions:

    • Adoptive immunotherapy, including DLIs, demonstrates significant potential in treating relapsed multiple myeloma.
    • Autologous T cell therapy shows promise for lymphoma recovery post-BMT, despite risks of autoimmune toxicity.